All News
BSR Guidelines for Giant Cell Arteritis
NICE has commissioned an update to the 2010 British Society for Rheumatology guideline for the management of giant cell arteritis, and proposed a total of 19 recommendations for the diagnosis and treatment of GCA.
Read ArticleRheumNow Podcast - RWCS Quick Hits (2.14.20)
Dr. Jack Cush reviews the highlights from the 2020 RWCS meeting in Maui, Hawaii.
Read ArticlePEXIVAS - Plasma Exhange Fails to Boost Outcomes in Severe AAV
The PEXIVAS study showed that plasma exchange did not reduce the incidence of death or ESKD in patients with severe ANCA–associated vasculitis.
Read ArticleShingles Vaccine Lowers Risk of CVA
Shingles infection has been historically linked to an increased risk of stroke. A new study found that Zoster Vaccine Live, one type of shingles vaccination, may prevent stroke in some older adults.
Read ArticleAlcohols Net Zero Effect in Rheumatoid Arthritis
A report from The National Databank for Rheumatic Disease addressed the impact of alcohol on disease activity and mortality in rheumatoid arthritis (RA) and found that alcohol use was not associated with changes in disease activity or mortality, after addressing confounders.
Read ArticleOvermedication of America
Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly.
Read ArticleHypersensitivity Reactions and Gout Tx: Watch the Dose
Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.
Read ArticleLarge UK database looked at 1281 Behcet Dz pts - prevalence of BD was 14.61 per 100k. BD was at increased risk of ischaemic heart disease [aHR 3.09), venous thrombosis [aHR 4.80] and mortality [aHR 1.40] iVS 5K controls. https://t.co/FghxE6bAZ0
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab Effective in Active Psoriatic Arthritis
Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.
Read ArticleDMARD Inertia by Registry Rheumatologists
A registry study of metric use (primarily RAPID3 and CDAI) in the treatment of rheumatoid arthritis (RA) patients shows that, even in the face of moderate or high disease activity, treatment changes by rheumatologists were relatively low (35.6–54.6%).
Read ArticleUpadacitinib Effective in Phase 3 Psoriatic Arthritis Study
Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.
Read ArticleRheumNow Podcast- Best Biologics (2.7.20)
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleBariatric Weight Loss Fails to Alter RA Risk
Obesity has been shown to be a risk factor for the onset of rheumatoid arthritis (RA) and also shown to affect outcomes by impairing responses to many DMARD therapies. A Swiss study of RA patients undergoing bariatric surgery failed to show that bariatric surgery and weight loss had any effect on the incidence of RA.
Read ArticleWhich Biologics are Best in Psoriasis
A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.
Read ArticleAspirin after Hip or Knee Arthoplasty
JAMA Internal Medicine has reported that use of low dose aspirin for venous thromboembolism (VTE) prophylaxis after total hip and knee replacement is equal in efficacy to other anticoagulants.
Read ArticleStart with Anti-TNF in RA? Not So Fast
The suggestion to hit rheumatoid arthritis (RA) early and hard with biologic therapies itself took a hit in a new study.
Read ArticleLimited Advantage to Very Early vs. Delayed Etanercept in RA
The VEDERA study sought to confirm whether the very early introduction of first-line etanercept+methotrexate (ETN+MTX) was superior to treat-to-target MTX (MTX-TT) in patients with early RA.
Read ArticleEULAR Recommendations on Sjögren’s Syndrome
The European League Against Rheumatism (EULAR) has established an international collaborative group (EULAR SS Task Force) to develop the first EULAR evidence and consensus-based recommendations for the management of patients with Sjogens syndrome (SjS).
Read ArticleHalf of Opioids Rx Come from 1% of MDs
The BMJ reports that while most US providers are cautious in their prescribing, half of opioid prescriptions are written by 1% of providers.
Between 2003 and 2017, there was an annual average of 669495 providers prescribing 8.9 million opioid prescriptions.
Read ArticleRheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article